Novartis AG
Regimens and methods of treating multiple sclerosis using ofatumumab

Abstract:

The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.